Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.

@article{Blanchard1994ResultsOE,
  title={Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.},
  author={Jean-Louis Blanchard and Luı́s Carreras and M Kindermans},
  journal={Nouvelle revue francaise d'hematologie},
  year={1994},
  volume={35 6},
  pages={523-8}
}
EMATAP, a randomized stratified, placebo-controlled double-blind multicentre trial was performed in Argentina in order to confirm the effect of ticlopidine in the prevention of thrombotic events in patients with intermittent claudication. Twenty-one clinical centres enrolled 615 patients, 304 (88 diabetic and 216 non diabetic) were assigned to the ticlopidine group and 311 (95 diabetic and 216 non diabetic) to the placebo group. Treatments were given for 24 weeks. The baseline characteristics… CONTINUE READING